But there are possible drivers of growth coming in the next 6-12 months with the BARDA trial and the chronic wound trial both coming to a conclusion and sales in India on top of what should be reasonable sales growth already pencilled in for FY25.
Ann: Appendix 4E and FY24 Financial Statements, page-19
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.05 |
Change
-0.020(0.97%) |
Mkt cap ! $1.416B | |||
| Open | High | Low | Value | Volume |
| $2.07 | $2.07 | $2.02 | $1.908M | 932.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4257 | $2.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.06 | 6318 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |